Amedisys Inc

Amedisys — Q2 2025 Earnings Presentation

11 slides from Amedisys's earnings presentation, Jul 29, 2025

  1. Slide 1: Amedisys Second Quarter 2025 Earnings Release Supplemental Slides

    1 Amedisys Second Quarter 2025 Earnings Release Supplemental Slides July 29, 2025 EXHIBIT 99.2

  2. Slide 2: Forward-Looking Statements

    2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could c

  3. Slide 3: Highlights and Summary Financial Results (Adjusted): 2Q'25

    3 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 2Q’25(1) 1. The financial results for the three-month periods ended June 30, 2024 and 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in

  4. Slide 4: Revenue Mix and Reimbursement by Payor

    4 54.3% 17.6% 28.1% Home Health Revenue Medicare FFS Private Episodic & Case Rate Per Visit 63.7% 34.6% 1.7% Amedisys Consolidated Revenue Home Health Hospice High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us for a 30

  5. Slide 5: Home Health and Hospice Segment (Adjusted) – 2Q'25

    5 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – 2Q’25(1) • Medicare revenue per episode up 0.7% primarily due to the 0.5% rate increase effective 1/1/2025. • Y/Y Total CPV up $2.68 (+2.3%) primarily due to raises, wage inflation, employee-related insurance costs and an increase in contract clinicians

  6. Slide 6: General & Administrative Expenses – Adjusted

    6 GENERAL & ADMINISTRATIVE EXPENSES – ADJUSTED (1,2) Notes: • Year over year total G&A as a percentage of revenue decreased 150 basis points • $0.6 million increase in total G&A is primarily due to planned wage increases and higher information technology costs partially offset by lower legal fees an

  7. Slide 7: Industry Leading Quality Scores

    7 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Jul 2025 HHC Final release with 89% of our providers (representing 89% of care centers) at 4+ Stars and 40% of our providers (representing 41% of care centers) at 4.

  8. Slide 8: Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class

    8 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. National is an average of all providers nationally, excluding active AMED providers. EXHIBIT 99.2

  9. Slide 9: Debt and Liquidity Metrics

    9 DEBT AND LIQUIDITY METRICS Net leverage ~0.1x 1. Net debt defined as total debt outstanding ($364.8M) less cash and cash equivalents ($337.3M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($262.4M). 3. Liquidity defined as the sum of cash balance an

  10. Slide 10: Cash Flow Statement Highlights

    10 CASH FLOW STATEMENT HIGHLIGHTS (1) 2Q’25 operating cash of $67M reflects strong accounts receivable collections. 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. $ in Millions 2Q24 3Q24 4Q24 1Q25 2Q25 GAAP net income (loss) 32.

  11. Slide 11: Income Statement Adjustments

    11 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025 have been adjusted for the certain items above. A reconciliation of our non-GAAP financial measures, which include the

Amedisys — Q2 2025 Earnings Presentation on 6ix